Clinical Trials Logo

HER2 Positive Breast Carcinoma clinical trials

View clinical trials related to HER2 Positive Breast Carcinoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04351230 Withdrawn - Clinical trials for Anatomic Stage IV Breast Cancer AJCC v8

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

Start date: November 11, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well T-DMI with or without abemaciclib works for the treatment of HER2-positive breast cancer that has spread to other places in the body (metastatic). T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called DM1. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers DM1 to kill them. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and abemaciclib may work better in treating patients with breast cancer compared to T-DM1 alone.